LOC729521 Inhibitors
The term LOC729521 Inhibitors refers to a class of chemical compounds that have been designed and developed with the primary aim of modulating the activity of the LOC729521 gene or its associated protein products. LOC729521, also known as LncRNA (Long non-coding RNA) 729521, is a non-coding RNA molecule found in humans and other organisms. It does not code for proteins like messenger RNAs (mRNAs) do but plays a crucial role in the regulation of various cellular processes, including gene expression, epigenetic modifications, and chromatin remodeling. Inhibitors targeting LOC729521 are specifically designed to interfere with the function or expression of this non-coding RNA, thereby influencing downstream molecular pathways and cellular functions.
Chemically, LOC729521 Inhibitors can take various forms, including small molecules, oligonucleotides, or other biologically active compounds. These inhibitors may function through several mechanisms, such as binding to LOC729521 RNA to prevent its interactions with other cellular components, altering its stability or degradation, or interfering with its transcription or translation processes. Understanding the precise mechanisms of action of these inhibitors is essential for elucidating their effects on cellular processes and uncovering novel strategies for modulating gene expression and cellular function. The development and study of LOC729521 Inhibitors contribute to our broader understanding of non-coding RNAs' roles in gene regulation and may have implications for future research in the field of molecular biology and genetics.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
A tyrosine kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFR. It blocks the activity of these enzymes, blocking the growth of cancer cells. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
An EGFR inhibitor that interferes with the growth of cancer cells by blocking the kinase activity of EGFR, reducing tumor growth. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
Targets and inhibits some mutated forms of BRAF kinase involved in the pathway of cell growth, leading to decreased tumor growth. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
A CDK4/6 inhibitor that halts the cell cycle by blocking cell cycle progression from G1 to S phase, thus inhibiting cancer cell growth. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Inhibits multiple kinases like Raf, VEGFR, and PDGFR, which are involved in tumor growth and angiogenesis. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
A MEK inhibitor that stops the MAPK/ERK pathway, thus blocking the growth of cancer cells. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that blocks the breakdown of proteins, leading to apoptosis of cancer cells. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
BCL-2 inhibitor that induces apoptosis in cancer cells by inhibiting the anti-apoptotic protein BCL-2. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Inhibits BCR-ABL and Src family kinases, hindering the progression of leukemia and other cancers. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $206.00 $299.00 $485.00 | 10 | |
PARP inhibitor that prevents DNA repair in cancer cells, leading to cell death, especially in BRCA-mutated cancers. | ||||||